Topiramate
Product Images NDC 68071-4756

4 FDA label images from Nucare Pharmaceuticals,inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 68071-4756). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4756 6

68071 4756 6
Topiramate 50 mg tablets label from NuCare Pharmaceuticals, Inc., NDC 68071-4756. The label indicates a bottle containing 60 round-shaped white/off-white tablets debossed with 'ZD 15' on one side. It includes instructions to take the medication as directed and storage conditions at controlled temperatures of 68-77°F. The label also shows manufacturing and lot information along with a barcode.*
FDA Label Image

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 01)

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 01)
Chemical structure diagram of topiramate, showing its molecular framework with key functional groups and stereochemistry illustrated.*
FDA Label Image

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 02)

Structured Product Formula For Topiramate (Af70d392 31a6 40bb 8f0a Ab51a70067fb 02)
A Kaplan-Meier survival curve graph depicting cumulative risk to first seizure over time (days) for two doses of topiramate, 50 mg/day and 400 mg/day, with sample sizes 234 and 236 respectively. The graph shows lower cumulative risk for the higher dose, with a p-value of 0.0002 indicating statistical significance.*
FDA Label Image

Topiramate Tablets Usp (Af70d392 31a6 40bb 8f0a Ab51a70067fb 03)

Topiramate Tablets Usp (Af70d392 31a6 40bb 8f0a Ab51a70067fb 03)
A bar graph showing change from baseline to double-blind phase in average monthly migraine period rate for topiramate at doses of 50 mg/day, 100 mg/day, and 200 mg/day compared to placebo across two studies. The y-axis represents change in migraine rate, with bars indicating values for Study 1 and Study 2 including error bars for standard error (SE). Sample sizes for each group are shown above the bars.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.